Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2025 10:00 ET | Source: NanoNewron

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimer’s Disease Program

NanoNewron awarded a $2.5 million NIH grant to develop TNF-α inhibitors engineered to cross the Blood-Brain Barrier to treat Alzheimer’s disease
March 04, 2025 15:13 ET | Source: NanoNewron

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound

Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier
February 20, 2025 12:30 ET | Source: NanoNewron

NanoNewron and its Research to Advance the Treatment of Alzheimer’s Disease are Featured by Rutgers University Newsletters and on Rutgers Today

NanoNewron, a biotech company developing biologics crossing the blood-brain barrier to treat Alzheimer’s, was featured by Rutgers University Newsletters